On October 23, the FDA approved belantamab mafodotin-blmf, a B-cell maturation antigen-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. For more information, read the FDA announcement and the GlaxoSmithKline press release.
On October 23, the FDA approved belantamab mafodotin-blmf, a B-cell maturation antigen-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
For more information, read the FDA announcement and the GlaxoSmithKline press release.
Posted on 10/27/2025
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
